Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
US moves: Potential generics boom - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jun 17, 2003

    US moves: Potential generics boom

    Indian pharma companies, which have been plagued by uncertainties that are likely to arise in the post-patent regime, have finally got something to cheer about. The US government has made two announcements, one in relation to reduction of approval time for generics and the other in respect of increasing the number of prescription drugs under the state funded health insurance scheme i.e. Medicare.

    The US government was under increasing pressure to bring down healthcare costs. As a result, it has announced a regulation that would bring down the time taken by generics to enter the market. Under the new regulations, the patent holder of a drug will not be able to stall the launch of the generic version by more than 30 months. This is likely to reduce generics approval time considerably. The increased budgetary allocation to the US-FDA generics department will help US-FDA to increase its approval staff and thus process the generics applications in less time. This will result in huge benefits to the Indian generic companies, as generics will be quickly introduced in the markets and also the legal expenses borne by companies to challenge an existing patent will come down.

    Apart from this, US government has also decided to provide a wider range of prescription drugs through Medicare. This will increase the demand for generics as it accounts for a major portion of the total prescriptions made. As Indian companies specialize in the export of generics to the US markets, a good portion of the fresh prescriptions is likely to be made in their favor.

    Among the Indian companies, Ranbaxy and Dr. Reddy’s Laboratories are likely to be the major beneficiaries of the above regulations. Let us briefly examine the advantage likely to be derived by these two companies.

    US Focus
    Company % of revenues
    from USA
    pending approval
    Ranbaxy 39 30
    Dr. Reddy's 32 23

    With over 30% of the revenues being derived from the US markets, widening of the number of prescription drugs in Medicare system and with 35 blockbuster drugs going off patent by 2005, the growth rates of these two companies will get a fresh impetus. Moreover, with 30 and 19 applications respectively pending with US-FDA for approval, the reduction in the approval time will further help the two companies in making rapid introduction of the generics in the market. The Indian companies will thus be able to further reduce their dependence on the Indian markets before product patents regulation comes into effect in 2005.

    Even for companies like Cipla, who till date have shown little visible signs of significant R&D expertise, the US move will open a lot of doors. The company can become a significant contract manufacturer for large MNCs who will now be under pressure to cut costs. All in all, a move that will bring smiles to the Indian pharma industry.



    Equitymaster requests your view! Post a comment on "US moves: Potential generics boom". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 21, 2017 12:01 PM